AAAAAA

   
Results: 1-10 |
Results: 10
Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit
Authors: Cheng, LY Rivero, ME Garcia, CR McDermott, CD Keefe, KS Wiley, CA Soules, KA Bergeron-Lynn, G Vekich, S Zhang, KY Appelt, K Freeman, WR
Citation: Ly. Cheng et al., Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit, J OCUL PH T, 17(3), 2001, pp. 295-304
The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy
Authors: Ozerdem, U Mach-Hofacre, B Keefe, K Pham, T Soules, K Appelt, K Freeman, WR
Citation: U. Ozerdem et al., The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy, OPHTHAL RES, 33(1), 2001, pp. 20-23
The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy
Authors: Ozerdem, U Mach-Hofacre, B Cheng, LY Chaidhawangul, S Keefe, K McDermott, CD Bergeron-Lynn, G Appelt, K Freeman, WR
Citation: U. Ozerdem et al., The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy, CURR EYE R, 20(6), 2000, pp. 447-453
Prinomastat - A potent and selective matrix metalloprotease inhibitor - Preclinical and clinical development for oncology
Authors: Shalinsky, DR Shetty, B Pithavala, Y Bender, S Neri, A Webber, S Appelt, K Collier, M
Citation: Dr. Shalinsky et al., Prinomastat - A potent and selective matrix metalloprotease inhibitor - Preclinical and clinical development for oncology, CANC DRUG, 2000, pp. 143-173
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
Authors: Shalinsky, DR Brekken, J Zou, H Bloom, LA McDermott, CD Zook, S Varki, NM Appelt, K
Citation: Dr. Shalinsky et al., Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies, CLIN CANC R, 5(7), 1999, pp. 1905-1917
Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
Authors: Price, A Shi, QA Morris, D Wilcox, ME Brasher, PMA Rewcastle, NB Shalinsky, D Zou, H Appelt, K Johnston, RN Yong, VW Edwards, D Forsyth, P
Citation: A. Price et al., Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340, CLIN CANC R, 5(4), 1999, pp. 845-854
Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis
Authors: McTigue, MA Wickersham, JA Pinko, C Showalter, RE Parast, CV Tempczyk-Russell, A Gehring, MR Mroczkowski, B Kan, CC Villafranca, JE Appelt, K
Citation: Ma. Mctigue et al., Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis, STRUCT F D, 7(3), 1999, pp. 319-330
The high-resolution structure of DNA-binding protein HU from Bacillus stearothermophilus
Authors: White, SW Wilson, KS Appelt, K Tanaka, I
Citation: Sw. White et al., The high-resolution structure of DNA-binding protein HU from Bacillus stearothermophilus, ACT CRYST D, 55, 1999, pp. 801-809
Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasmaconcentrations
Authors: Shalinsky, DR Brekken, J Zou, H Kolis, S Wood, A Webber, S Appelt, K
Citation: Dr. Shalinsky et al., Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasmaconcentrations, INV NEW DR, 16(4), 1998, pp. 303-313
Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis
Authors: Parast, CV Mroczkowski, B Pinko, C Misialek, S Khambatta, G Appelt, K
Citation: Cv. Parast et al., Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis, BIOCHEM, 37(47), 1998, pp. 16788-16801
Risultati: 1-10 |